Acadia Pharmaceuticals (ACAD) Common Equity (2010 - 2026)

Acadia Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 63.1% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 63.1% YoY), and the FY2025 full-year result was $1.2 billion, up 67.49% from the prior year.
• Common Equity for Q1 2026 stood at $1.2 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Common Equity was $1.2 billion in Q1 2026, with the low at $362.2 million in Q3 2023.
• Average Common Equity over 5 years is $620.0 million, with a median of $464.0 million recorded in 2024.
• Year-over-year, Common Equity dropped 25.97% in 2022 and surged 69.72% in 2024.
• Tracing ACAD's Common Equity over 5 years: stood at $400.4 million in 2022, then gained by 7.83% to $431.8 million in 2023, then surged by 69.72% to $732.8 million in 2024, then jumped by 67.49% to $1.2 billion in 2025, then gained by 1.68% to $1.2 billion in 2026.
• The last three Common Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $917.3 million (Q3 2025), per Business Quant data.

Peer Comparison